Phase 0 Study in Healthy, Hepatic and Renal Impaired Subjects to Obtain Plasma for Lenvatinib Protein Binding

Inclusion Criteria: Key Inclusion Criteria: * Male or Female * Age, at the time of Informed Consent: i. Hepatic Impairment Participants (Including Matched Healthy Participants): 18 to 70 years old, inclusive ii. Renal Impairment Participants (Including Matched Healthy Participants): 18 to 79 years old, inclusive * Non-smokers and smokers who smoke no more than 10 cigarettes per day * Besides diabetes and, as appropriate, renal or hepatic impairment, participants must have no history of acute or chronic clinically relevant disease or condition, as determined by the investigator. * For participants with hepatic impairment: * Liver cirrhosis that has been stable; * Platelet count \>30,000 cells/millimeter cubed (mm\^3); * Total score on the Child-Pugh classification system between 5 and 6 (Group 1, mild), 7 and 9 (Group 2, moderate), and 10 and 15 (Group 3, severe) * For healthy participants: • Creatinine clearance ≥ 81 milliliter per minute (mL/min) * For participants with renal impairment: * Must have a diagnosis of renal impairment that has been stable * Must have renal impairment in the following categories based on creatinine clearance values: mild (creatinine clearance, 50 to 80 mL/min), moderate (creatinine clearance, 30 to 49 mL/min), or severe (creatinine clearance, 15 to 29 mL/min) renal impairment Exclusion Criteria: Key Exclusion Criteria: * Use of any new medication * Human immunodeficiency virus (HIV) positive * Presence of acute active liver disease or acute liver injury * History of significant cardiovascular impairment * Positive drug or alcohol test * Weight loss or gain of \>10% prior to Day 1 * Receipt of blood or blood products or donation of blood or blood products For participants with hepatic impairment: * History of hepatic transplant, systemic lupus erythematosus, or hepatic coma * Received treatment with interferon or pegylated interferon * Participants who have encephalopathy \>Grade 2, sepsis, or gastrointestinal bleeding; esophageal varices \>Grade 2, acute hepatic failure of any etiology, history of surgical portosystemic shunt, renal impairment (creatinine clearance \<50 mL/min according to the Cockcroft-Gault formula), and rapidly deteriorating hepatic function * Systolic blood pressure (SBP) ≥ 160 millimeters of mercury (mmHg) and/or diastolic blood pressure (DBP) ≥ 100 mmHg For healthy participants: • Hemoglobin level less than 12.0 grams per deciliter (g/dL) For participants with renal impairment: * A history of renal transplant * SBP ≥ 160 mmHg and/or DBP ≥ 100 mmHg for participants with mild renal impairment; SBP ≥ 180 mmHg and/or DBP ≥ 110 mmHg for participants with moderate and severe renal impairment * Significant bleeding diathesis